<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02266381</url>
  </required_header>
  <id_info>
    <org_study_id>MRER(29)2014</org_study_id>
    <nct_id>NCT02266381</nct_id>
  </id_info>
  <brief_title>A Prospective Comparison of Fluoroscopic, Sonographic or Combined Approach for Renal Access in Percutaneous Nephrolithotomy</brief_title>
  <official_title>A Prospective and Randomized Comparison of Fluoroscopic, Sonographic or Combined Approach for Renal Access in Percutaneous Nephrolithotomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose:

      The aim of this present study is to compare the result of fluoroscopy, ultrasonography (US)
      and US combined with fluoroscopy in the guidance of minimally invasive percutaneous
      nephrolithotomy (MPCNL).

      Methods:

      The investigators will enroll 450 patients who are candidates for MPCNL in our study. By
      simple random sampling technique, patients will be assigned to three 150-patient groups
      (group 1, US-guided MPCNL, group 2, fluoroscopy-guided MPCNL and group 3, US combined with
      fluoroscopy-guided MPCNL). In addition to approaches in guidance of MPCNL, the rest of the
      procedure is the same in all three groups.The end point of the study is the comparison of
      outcome of procedure including stone free rate, transfusion rate, operation time, access
      time, length of stay and complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:

      Recently, PCNL or MPCNL is widely used as the most popular choice to treat patients with all
      types of renal stones. Successful puncture to the desired renal calyx is the key step for the
      operation. Nowadays puncture for renal access can be achieve using not only US guidance but
      fluoroscopy guidance as well. However, it is clear that there is a lack of randomized
      controlled data comparing fluoroscopy, US and US combined with fluoroscopy in the guidance of
      MPCNL. Consequently, we performed this randomized controlled trial to obtain higher grade
      evidence.The aim of this present study is to compare the result of fluoroscopy, US and US
      combined with fluoroscopy in the guidance of MPCNL.

      Methods:

      We will enroll 450 patients who are candidates for MPCNL in our study. By simple random
      sampling technique, patients will be assigned to three 150-patient groups (group 1, US-guided
      MPCNL, group 2, fluoroscopy-guided MPCNL and group 3, US combined with fluoroscopy-guided
      MPCNL).

      All the patients will be diagnosed definitely before operations with kidney, ureter, and
      bladder (KUB), intravenous pyelography (IVP), US and/or CT.

      All procedures are performed by urologists in our center, with assistance from an endourology
      fellow.

      Surgical technique:

      Under general or epidural anaesthesia, each patient is initially placed in the lithotomy
      position, and a 5 Fr ureteric catheter is advanced to the kidney and fixed with a 16 Fr Foley
      catheter. Then the patient is turned to the prone position.

      Group 1: US-guided MPCNL The puncture is made with an 18-gauge needle using an ultrasound
      probe. After the desirable calix is reached, a flexible-tip guidewire is introduced. We
      attempt to manipulate the guidewire down to the ureter. If this is not successful, the second
      choice is to allow the guidewire to coil in a more distant calix. The length of the needle
      from skin to the collecting system is measured to ensure that the length of dilator is
      appropriate. The access tract is dilated from 8 Fr to a maximum 18/20 Fr using fascial
      dilator. We defined access to the collecting system as gaining entry to the targeted urinary
      system and desired calix.

      Lithotripsy is performed using either pneumatic lithotriptor or holmium laser. When multiple
      nephrostomy tracts are necessary to remove the stones, same technique is employed for each of
      the tracts.

      Complete stone clearance is confirmed using US at completion of the procedure. We routinely
      put a double J ureteral catheter into the ureter which is to be removed about 3-4 weeks later
      after the operation in the out-patients clinic. At the end of the procedure nephrostomy tubes
      are placed in both groups. The tubes are removed when the drainage from nephrostomy tubes
      being grossly clear.

      Group 2 fluoroscopy-guided MPCNL Patients in group 2 have the standard fluoroscopy-guided
      renal access before MPCNL. Air or contrast medium is injected through the ureteral catheter,
      the target calix is identified. For tract dilatation fascial dilators are used under
      fluoroscopic guidance.

      Complete stone clearance is confirmed fluoroscopically at completion of the procedure.

      The rest of the procedure is the same as described for patients in group 1.

      Group 3 US combined with fluoroscopy-guided MPCNL:

      Under the guidance of ultrasound, the coaxial needle is placed in the desired calyx. A
      floppy-tipped guidewire is then passed through the needle into the collecting system. The
      working channel is then dilated under X-ray.

      US and X-ray check for residual stone fragments are performed at the end of the procedure.

      The rest of the procedure is the same as described for patients in group 1.

      Data collection:

      Data for the three groups -demographic characteristics, access success, access time, duration
      of radiation exposure, site of target calix, site of access, Hb decrease, duration of
      postoperative hospital stay, complications (modified Clavien system), stone clearance (SFR
      after single procedure and final SFR) and the need for auxiliary treatment - are compared.

      The primary end point of the study is the comparison of outcome of procedure including stone
      free rate, transfusion rate, operation time, access time, length of stay and complications.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stone Free Rate</measure>
    <time_frame>one day after MPCNL</time_frame>
    <description>Stone-free status is assessed by kidneys-ureter-bladder (KUB) or/ and noncontrast CT at day 1 after MPCNL. A stone-free state is defined as no residual stones of diameter &gt;4 mm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perioperative Complications</measure>
    <time_frame>intraoperatively or ≤ 30 days postoperatively</time_frame>
    <description>Complication is defined as any adverse event occurred intraoperatively or ≤ 30 days postoperatively. Complications included fever, systemic Inflammatory Response Syndrome, septic shock, extravasations, bleeding necessitating transfusion, and sever bleeding necessitating selective renal artery embolization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operation Time</measure>
    <time_frame>intraoperatively</time_frame>
    <description>Operation time is defined as the time from puncture to the placement of the nephrostomy tube.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin Concentration</measure>
    <time_frame>within 24 hours after MPCNL</time_frame>
    <description>Change in hemoglobin concentration is assessed by comparing the preoperative hemoglobin level with 24-hour postoperative hemoglobin level.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">450</enrollment>
  <condition>Urolithiasis</condition>
  <arm_group>
    <arm_group_label>US-guided group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in US-guided group undergo MPCNL using only US-guided renal access.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluoroscopy-guided group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in Fluoroscopy-guided group undergo MPCNL using only fluoroscopy-guided renal access.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined-guided group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in Combined-guided group undergo MPCNL using US combined with fluoroscopy-guided renal access.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>US-guided renal access</intervention_name>
    <description>Patients undergo MPCNL using only US-guided renal access.</description>
    <arm_group_label>US-guided group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fluoroscopy-guided renal access</intervention_name>
    <description>Patients undergo MPCNL using only fluoroscopy-guided renal access.</description>
    <arm_group_label>Fluoroscopy-guided group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>US combined with fluoroscopy-guided renal access</intervention_name>
    <description>Patients undergo MPCNL using US combined with fluoroscopy-guided renal access</description>
    <arm_group_label>Combined-guided group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal renal function.

          -  American society of Anesthesiology (ASA) score 1 and 2.

          -  Absence of congenital abnormalities.

          -  Kidney stones of diameter &gt; 2.0cm (including multiple and staghorn stones)

        Exclusion Criteria:

          -  Patients with congenital anomalies, e.g. ectopic kidney, polycystic, horseshoe, or
             malrotated kidney.

          -  Patients who underwent transplant or urinary diversion.

          -  Patients with solitary kidney.

          -  Patients will be excluded from the study if they undergoing MPCNL have purulent fluid
             in the initial puncture.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guohua Zeng, PH.D and M.D</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital of Guangzhou Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510230</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Lu MH, Pu XY, Gao X, Zhou XF, Qiu JG, Si-Tu J. A comparative study of clinical value of single B-mode ultrasound guidance and B-mode combined with color doppler ultrasound guidance in mini-invasive percutaneous nephrolithotomy to decrease hemorrhagic complications. Urology. 2010 Oct;76(4):815-20. doi: 10.1016/j.urology.2009.08.091. Epub 2010 Jun 25.</citation>
    <PMID>20579695</PMID>
  </reference>
  <reference>
    <citation>Mozer P, Conort P, Leroy A, Baumann M, Payan Y, Troccaz J, Chartier-Kastler E, Richard F. Aid to percutaneous renal access by virtual projection of the ultrasound puncture tract onto fluoroscopic images. J Endourol. 2007 May;21(5):460-5.</citation>
    <PMID>17523896</PMID>
  </reference>
  <reference>
    <citation>Yan S, Xiang F, Yongsheng S. Percutaneous nephrolithotomy guided solely by ultrasonography: a 5-year study of &gt;700 cases. BJU Int. 2013 Nov;112(7):965-71. doi: 10.1111/bju.12248. Epub 2013 Jul 26.</citation>
    <PMID>23889729</PMID>
  </reference>
  <reference>
    <citation>Li X, Long Q, Chen X, He D, He H. Real-time ultrasound-guided PCNL using a novel SonixGPS needle tracking system. Urolithiasis. 2014 Aug;42(4):341-6. doi: 10.1007/s00240-014-0671-2. Epub 2014 Jun 26. Erratum in: Urolithiasis. 2014 Oct;42(5):473. Dalin, He [corrected to He, Dalin].</citation>
    <PMID>24965272</PMID>
  </reference>
  <reference>
    <citation>Agarwal M, Agrawal MS, Jaiswal A, Kumar D, Yadav H, Lavania P. Safety and efficacy of ultrasonography as an adjunct to fluoroscopy for renal access in percutaneous nephrolithotomy (PCNL). BJU Int. 2011 Oct;108(8):1346-9. doi: 10.1111/j.1464-410X.2010.10002.x. Epub 2011 Jan 20.</citation>
    <PMID>21251187</PMID>
  </reference>
  <reference>
    <citation>Opondo D, Gravas S, Joyce A, Pearle M, Matsuda T, Sun YH, Assimos D, Denstedt J, de la Rosette J. Standardization of patient outcomes reporting in percutaneous nephrolithotomy. J Endourol. 2014 Jul;28(7):767-74. doi: 10.1089/end.2014.0057. Epub 2014 Apr 16. Review.</citation>
    <PMID>24571713</PMID>
  </reference>
  <reference>
    <citation>Basiri A, Ziaee AM, Kianian HR, Mehrabi S, Karami H, Moghaddam SM. Ultrasonographic versus fluoroscopic access for percutaneous nephrolithotomy: a randomized clinical trial. J Endourol. 2008 Feb;22(2):281-4. doi: 10.1089/end.2007.0141.</citation>
    <PMID>18294034</PMID>
  </reference>
  <reference>
    <citation>Desai M, Jain P, Ganpule A, Sabnis R, Patel S, Shrivastav P. Developments in technique and technology: the effect on the results of percutaneous nephrolithotomy for staghorn calculi. BJU Int. 2009 Aug;104(4):542-8; discussion 548. doi: 10.1111/j.1464-410X.2009.08472.x. Epub 2009 Mar 6.</citation>
    <PMID>19298409</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2014</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2014</study_first_posted>
  <results_first_submitted>August 4, 2016</results_first_submitted>
  <results_first_submitted_qc>September 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 9, 2016</results_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Guohua Zeng</investigator_full_name>
    <investigator_title>Vice President of the Hospital</investigator_title>
  </responsible_party>
  <keyword>PCNL</keyword>
  <keyword>MPCNL</keyword>
  <keyword>guidance</keyword>
  <keyword>puncture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urolithiasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A prospective and randomized study was performed with patient enrollment from July 2014 to May 2015 in the First Affilated Hospital of Guangzhou Medical University. 450 patients were then randomized into three groups. 12 patients had purulent fluid in the kidney at initial punctures. These 12 patients were excluded from the analysis.</recruitment_details>
      <pre_assignment_details>549 consecutive patients were assessed for eligibility, 99 were excluded for not meeting the inclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>US-guided Group</title>
          <description>Patients in US-guided group undergo MPCNL using only US-guided renal access.</description>
        </group>
        <group group_id="P2">
          <title>Fluoroscopy-guided Group</title>
          <description>Patients in Fluoroscopy-guided group undergo MPCNL using only fluoroscopy-guided renal access.</description>
        </group>
        <group group_id="P3">
          <title>Combined-guided Group</title>
          <description>Patients in combined-guided group undergo MPCNL using US combined with fluoroscopy-guided renal access.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="150"/>
                <participants group_id="P3" count="150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="145"/>
                <participants group_id="P3" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>450 patients were then randomized into three groups.12 patients had purulent fluid in the kidney at initial punctures. A nephrostomy tube was placed and MPCNL postponed to avoid septic complications. These 12 patients were excluded from the analysis. Finally, 438 patients were accrued in the analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>US-guided Group</title>
          <description>Patients in US-guided group undergo MPCNL using only US-guided renal access.</description>
        </group>
        <group group_id="B2">
          <title>Fluoroscopy-guided Group</title>
          <description>Patients in Fluoroscopy-guided group undergo MPCNL using only fluoroscopy-guided renal access.</description>
        </group>
        <group group_id="B3">
          <title>Combined-guided Group</title>
          <description>Patients in Combined-guided group undergo MPCNL using US combined with fluoroscopy-guided renal access.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="147"/>
            <count group_id="B2" value="145"/>
            <count group_id="B3" value="146"/>
            <count group_id="B4" value="438"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.9" spread="10.9"/>
                    <measurement group_id="B2" value="49.6" spread="11.3"/>
                    <measurement group_id="B3" value="48.8" spread="11.3"/>
                    <measurement group_id="B4" value="49.4" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="146"/>
                    <measurement group_id="B4" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Stone Free Rate</title>
        <description>Stone-free status is assessed by kidneys-ureter-bladder (KUB) or/ and noncontrast CT at day 1 after MPCNL. A stone-free state is defined as no residual stones of diameter &gt;4 mm.</description>
        <time_frame>one day after MPCNL</time_frame>
        <group_list>
          <group group_id="O1">
            <title>US-guided Group</title>
            <description>Patients in US-guided group undergo MPCNL using only US-guided renal access.</description>
          </group>
          <group group_id="O2">
            <title>Fluoroscopy-guided Group</title>
            <description>Patients in Fluoroscopy-guided group undergo MPCNL using only fluoroscopy-guided renal access.</description>
          </group>
          <group group_id="O3">
            <title>Combined-guided Group</title>
            <description>Patients in Combined-guided group undergo MPCNL using US combined with fluoroscopy-guided renal access.</description>
          </group>
        </group_list>
        <measure>
          <title>Stone Free Rate</title>
          <description>Stone-free status is assessed by kidneys-ureter-bladder (KUB) or/ and noncontrast CT at day 1 after MPCNL. A stone-free state is defined as no residual stones of diameter &gt;4 mm.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perioperative Complications</title>
        <description>Complication is defined as any adverse event occurred intraoperatively or ≤ 30 days postoperatively. Complications included fever, systemic Inflammatory Response Syndrome, septic shock, extravasations, bleeding necessitating transfusion, and sever bleeding necessitating selective renal artery embolization.</description>
        <time_frame>intraoperatively or ≤ 30 days postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>US-guided Group</title>
            <description>Patients in US-guided undergo MPCNL using only US-guided renal access.</description>
          </group>
          <group group_id="O2">
            <title>Fluoroscopy-guided Group</title>
            <description>Patients in Fluoroscopy-guided group undergo MPCNL using only fluoroscopy-guided renal access.</description>
          </group>
          <group group_id="O3">
            <title>Combined Group</title>
            <description>Patients in Combined group undergo MPCNL using US combined with fluoroscopy-guided renal access.</description>
          </group>
        </group_list>
        <measure>
          <title>Perioperative Complications</title>
          <description>Complication is defined as any adverse event occurred intraoperatively or ≤ 30 days postoperatively. Complications included fever, systemic Inflammatory Response Syndrome, septic shock, extravasations, bleeding necessitating transfusion, and sever bleeding necessitating selective renal artery embolization.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Operation Time</title>
        <description>Operation time is defined as the time from puncture to the placement of the nephrostomy tube.</description>
        <time_frame>intraoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>US-guided Group</title>
            <description>Patients in US-guided group undergo MPCNL using only US-guided renal access.</description>
          </group>
          <group group_id="O2">
            <title>Fluoroscopy-guided Group</title>
            <description>Patients in Fluoroscopy-guided group undergo MPCNL using only fluoroscopy-guided renal access.</description>
          </group>
          <group group_id="O3">
            <title>Combined-guided Group</title>
            <description>Patients in Combined-guided group undergo MPCNL using US combined with fluoroscopy-guided renal access.</description>
          </group>
        </group_list>
        <measure>
          <title>Operation Time</title>
          <description>Operation time is defined as the time from puncture to the placement of the nephrostomy tube.</description>
          <units>min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.6" spread="32.9"/>
                    <measurement group_id="O2" value="63.6" spread="32.5"/>
                    <measurement group_id="O3" value="66.3" spread="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin Concentration</title>
        <description>Change in hemoglobin concentration is assessed by comparing the preoperative hemoglobin level with 24-hour postoperative hemoglobin level.</description>
        <time_frame>within 24 hours after MPCNL</time_frame>
        <group_list>
          <group group_id="O1">
            <title>US-guided Group</title>
            <description>Patients in US-guided group undergo MPCNL using only US-guided renal access.</description>
          </group>
          <group group_id="O2">
            <title>Fluoroscopy-guided Group</title>
            <description>Patients in Fluoroscopy-guided group undergo MPCNL using only fluoroscopy-guided renal access.</description>
          </group>
          <group group_id="O3">
            <title>Combined-guided Group</title>
            <description>Patients in Combined-guided group undergo MPCNL using US combined with fluoroscopy-guided renal access.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin Concentration</title>
          <description>Change in hemoglobin concentration is assessed by comparing the preoperative hemoglobin level with 24-hour postoperative hemoglobin level.</description>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="16.0"/>
                    <measurement group_id="O2" value="14.5" spread="10.0"/>
                    <measurement group_id="O3" value="13.1" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>US-guided Group</title>
          <description>Patients in US-guided group undergo MPCNL using only US-guided renal access.</description>
        </group>
        <group group_id="E2">
          <title>Fluoroscopy-guided Group</title>
          <description>Patients in Fluoroscopy-guided group undergo MPCNL using only fluoroscopy-guided renal access.</description>
        </group>
        <group group_id="E3">
          <title>Combined-guided Group</title>
          <description>Patients in Combined-guided group undergo MPCNL using US combined with fluoroscopy-guided renal access.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Perioperative complications</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="145"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Guohua Zeng</name_or_title>
      <organization>The First Affiliated Hospital of Guangzhou Medical University</organization>
      <phone>0086-20-34294163</phone>
      <email>gzgyzgh@vip.sina.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

